R
Roger Stupp
Researcher at Northwestern University
Publications - 463
Citations - 73077
Roger Stupp is an academic researcher from Northwestern University. The author has contributed to research in topics: Temozolomide & Glioma. The author has an hindex of 93, co-authored 430 publications receiving 63025 citations. Previous affiliations of Roger Stupp include Merck & Co. & University of St. Gallen.
Papers
More filters
Journal ArticleDOI
Guidelines on management of low-grade gliomas: report of an EFNS–EANO* Task Force
Riccardo Soffietti,Brigitta G. Baumert,Lorenzo Bello,A. von Deimling,Hugues Duffau,Marc Frenay,Wolfgang Grisold,Robin Grant,Francesc Graus,Khê Hoang-Xuan,Martin Klein,Beatrice Melin,Jeremy Rees,Tali Siegal,Anja Smits,Roger Stupp,Wolfgang Wick +16 more
TL;DR: Diffuse infiltrative low‐grade gliomas of the cerebral hemispheres in the adult are a group of tumors with distinct clinical, histological and molecular characteristics, and there are still controversies in management.
Journal ArticleDOI
Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial
René O. Mirimanoff,Thierry Gorlia,Warren P. Mason,Martin J. van den Bent,Rolf-Dieter Kortmann,Barbara Fisher,Michele Reni,Alba A. Brandes,Jüergen Curschmann,Salvador Villà,Gregory Cairncross,Anouk Allgeier,Denis Lacombe,Roger Stupp +13 more
TL;DR: RPA retains its prognostic significance overall as well as in patients receiving RT with or without TMZ for newly diagnosed GBM, particularly in classes III and IV.
Journal ArticleDOI
Current concepts and management of glioblastoma.
Matthias Preusser,Sandrine de Ribaupierre,Adelheid Wöhrer,Sara Erridge,Monika E. Hegi,Michael Weller,Roger Stupp +6 more
TL;DR: This review covers major aspects of care of glioblastoma patients with a focus on the management of common symptoms and complications, and aims to provide a guide for clinicians confronted with gliobeastoma patients in their everyday practice.
Journal ArticleDOI
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
Roger Stupp,Monika E. Hegi,Bart Neyns,Roland Goldbrunner,Uwe Schlegel,Paul Clement,Gerhard G. Grabenbauer,Adrian F. Ochsenbein,Matthias Simon,Pierre-Yves Dietrich,Torsten Pietsch,Christine Hicking,Joerg C. Tonn,Annie Claire Diserens,Alessia Pica,Mirjam Hermisson,Stefan R. Krueger,Martin Picard,Michael Weller +18 more
TL;DR: Compared with historical controls, the addition of concomitant and adjuvant cilengitide to standard chemoradiotherapy demonstrated promising activity in patients with glioblastoma with MGMT promoter methylation.
Journal ArticleDOI
Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients
Sandrine Ostermann,Chantal Csajka,Thierry Buclin,Serge Leyvraz,Ferdy J. Lejeune,Laurent A. Decosterd,Roger Stupp +6 more
TL;DR: This is the first human pharmacokinetic study on TMZ to quantify CSF penetration and systemic or cerebral exposures are not better predictors than the cumulative dose alone for both efficacy and safety.